Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
Latest Information Update: 11 Aug 2023
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Cynapsus Therapeutics; Sunovion Pharmaceuticals
- 18 Sep 2022 Results (n=109) of a post-hoc analysis assessing patients reported outcomes data from diary entries presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
- 18 Sep 2022 Results presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
- 22 Sep 2021 Results(n=307) of matching-adjusted indirect comparison (MAIC) from CTH-300 and SPAN-PD assessing efficacy of apomorphine sublingual film vs levodopa inhalation powder (CVT-301) for OFF episodes in Parkinson's disease (PD) presented at the 25th International Congress of Parkinson's Disease and Movement Disorders